{"id":1055,"date":"2019-09-12T13:03:12","date_gmt":"2019-09-12T13:03:12","guid":{"rendered":"https:\/\/be.alfasigma.com\/?post_type=press_coverage&#038;p=1055"},"modified":"2020-11-23T15:36:39","modified_gmt":"2020-11-23T15:36:39","slug":"alfasigma-usa-reintroduces-ibs-c-drug-zelnorm-to-u-s-market","status":"publish","type":"press_coverage","link":"https:\/\/be.alfasigma.com\/nl\/press_coverage\/alfasigma-usa-reintroduces-ibs-c-drug-zelnorm-to-u-s-market\/","title":{"rendered":"Alfasigma USA Reintroduces IBS-C Drug Zelnorm to U.S. Market"},"template":"","meta":{"_acf_changed":false},"class_list":["post-1055","press_coverage","type-press_coverage","status-publish","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Alfasigma USA Reintroduces IBS-C Drug Zelnorm to U.S. Market - Alfasigma BE<\/title>\n<meta name=\"robots\" content=\"index,follow\" \/>\n<link rel=\"canonical\" href=\"https:\/\/be.alfasigma.com\/nl\/press_coverage\/alfasigma-usa-reintroduces-ibs-c-drug-zelnorm-to-u-s-market\/\" \/>\n<meta property=\"og:locale\" content=\"nl_NL\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Alfasigma USA Reintroduces IBS-C Drug Zelnorm to U.S. Market - Alfasigma BE\" \/>\n<meta property=\"og:url\" content=\"https:\/\/be.alfasigma.com\/nl\/press_coverage\/alfasigma-usa-reintroduces-ibs-c-drug-zelnorm-to-u-s-market\/\" \/>\n<meta property=\"og:site_name\" content=\"Alfasigma BE\" \/>\n<meta property=\"article:modified_time\" content=\"2020-11-23T15:36:39+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/be.alfasigma.com\\\/nl\\\/press_coverage\\\/alfasigma-usa-reintroduces-ibs-c-drug-zelnorm-to-u-s-market\\\/\",\"url\":\"https:\\\/\\\/be.alfasigma.com\\\/nl\\\/press_coverage\\\/alfasigma-usa-reintroduces-ibs-c-drug-zelnorm-to-u-s-market\\\/\",\"name\":\"Alfasigma USA Reintroduces IBS-C Drug Zelnorm to U.S. Market - Alfasigma BE\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/be.alfasigma.com\\\/nl\\\/#website\"},\"datePublished\":\"2019-09-12T13:03:12+00:00\",\"dateModified\":\"2020-11-23T15:36:39+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/be.alfasigma.com\\\/nl\\\/press_coverage\\\/alfasigma-usa-reintroduces-ibs-c-drug-zelnorm-to-u-s-market\\\/#breadcrumb\"},\"inLanguage\":\"nl-NL\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/be.alfasigma.com\\\/nl\\\/press_coverage\\\/alfasigma-usa-reintroduces-ibs-c-drug-zelnorm-to-u-s-market\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/be.alfasigma.com\\\/nl\\\/press_coverage\\\/alfasigma-usa-reintroduces-ibs-c-drug-zelnorm-to-u-s-market\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/be.alfasigma.com\\\/nl\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Press Coverages\",\"item\":\"https:\\\/\\\/be.alfasigma.com\\\/nl\\\/press_coverage\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Alfasigma USA Reintroduces IBS-C Drug Zelnorm to U.S. Market\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/be.alfasigma.com\\\/nl\\\/#website\",\"url\":\"https:\\\/\\\/be.alfasigma.com\\\/nl\\\/\",\"name\":\"Alfasigma BE\",\"description\":\"Pharmaceuticals with passion\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/be.alfasigma.com\\\/nl\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"nl-NL\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Alfasigma USA Reintroduces IBS-C Drug Zelnorm to U.S. Market - Alfasigma BE","robots":{"index,follow":"index,follow"},"canonical":"https:\/\/be.alfasigma.com\/nl\/press_coverage\/alfasigma-usa-reintroduces-ibs-c-drug-zelnorm-to-u-s-market\/","og_locale":"nl_NL","og_type":"article","og_title":"Alfasigma USA Reintroduces IBS-C Drug Zelnorm to U.S. Market - Alfasigma BE","og_url":"https:\/\/be.alfasigma.com\/nl\/press_coverage\/alfasigma-usa-reintroduces-ibs-c-drug-zelnorm-to-u-s-market\/","og_site_name":"Alfasigma BE","article_modified_time":"2020-11-23T15:36:39+00:00","twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/be.alfasigma.com\/nl\/press_coverage\/alfasigma-usa-reintroduces-ibs-c-drug-zelnorm-to-u-s-market\/","url":"https:\/\/be.alfasigma.com\/nl\/press_coverage\/alfasigma-usa-reintroduces-ibs-c-drug-zelnorm-to-u-s-market\/","name":"Alfasigma USA Reintroduces IBS-C Drug Zelnorm to U.S. Market - Alfasigma BE","isPartOf":{"@id":"https:\/\/be.alfasigma.com\/nl\/#website"},"datePublished":"2019-09-12T13:03:12+00:00","dateModified":"2020-11-23T15:36:39+00:00","breadcrumb":{"@id":"https:\/\/be.alfasigma.com\/nl\/press_coverage\/alfasigma-usa-reintroduces-ibs-c-drug-zelnorm-to-u-s-market\/#breadcrumb"},"inLanguage":"nl-NL","potentialAction":[{"@type":"ReadAction","target":["https:\/\/be.alfasigma.com\/nl\/press_coverage\/alfasigma-usa-reintroduces-ibs-c-drug-zelnorm-to-u-s-market\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/be.alfasigma.com\/nl\/press_coverage\/alfasigma-usa-reintroduces-ibs-c-drug-zelnorm-to-u-s-market\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/be.alfasigma.com\/nl\/"},{"@type":"ListItem","position":2,"name":"Press Coverages","item":"https:\/\/be.alfasigma.com\/nl\/press_coverage\/"},{"@type":"ListItem","position":3,"name":"Alfasigma USA Reintroduces IBS-C Drug Zelnorm to U.S. Market"}]},{"@type":"WebSite","@id":"https:\/\/be.alfasigma.com\/nl\/#website","url":"https:\/\/be.alfasigma.com\/nl\/","name":"Alfasigma BE","description":"Pharmaceuticals with passion","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/be.alfasigma.com\/nl\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"nl-NL"}]}},"_links":{"self":[{"href":"https:\/\/be.alfasigma.com\/nl\/wp-json\/wp\/v2\/press_coverage\/1055","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/be.alfasigma.com\/nl\/wp-json\/wp\/v2\/press_coverage"}],"about":[{"href":"https:\/\/be.alfasigma.com\/nl\/wp-json\/wp\/v2\/types\/press_coverage"}],"version-history":[{"count":3,"href":"https:\/\/be.alfasigma.com\/nl\/wp-json\/wp\/v2\/press_coverage\/1055\/revisions"}],"predecessor-version":[{"id":2693,"href":"https:\/\/be.alfasigma.com\/nl\/wp-json\/wp\/v2\/press_coverage\/1055\/revisions\/2693"}],"wp:attachment":[{"href":"https:\/\/be.alfasigma.com\/nl\/wp-json\/wp\/v2\/media?parent=1055"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}